COX.PA Stock - Nicox S.A.
Unlock GoAI Insights for COX.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $5.24M | $8.58M | $14.42M | $8.26M | $4.72M |
| Gross Profit | $3.27M | $7.23M | $12.91M | $6.86M | $4.03M |
| Gross Margin | 62.4% | 84.3% | 89.5% | 83.0% | 85.4% |
| Operating Income | $-21,696,000 | $-17,622,000 | $-7,013,000 | $-18,324,000 | $-20,970,000 |
| Net Income | $-27,759,000 | $-43,761,000 | $-18,098,000 | $-18,922,000 | $-18,391,000 |
| Net Margin | -529.5% | -509.9% | -125.5% | -229.1% | -389.9% |
| EPS | $-0.74 | $-1.17 | $-0.54 | $-0.62 | $-0.62 |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
Visit WebsiteEarnings History & Surprises
COX.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Apr 19, 2023 | — | — | — | — |
Q1 2023 | Jan 18, 2023 | — | — | — | — |
Q4 2013 | Dec 31, 2013 | — | $-0.58 | — | — |
Q2 2013 | Jun 30, 2013 | — | $-0.63 | — | — |
Q4 2012 | Dec 31, 2012 | — | $-0.68 | — | — |
Q2 2012 | Jun 30, 2012 | — | $-0.02 | — | — |
Q4 2011 | Dec 31, 2011 | — | $-0.61 | — | — |
Q2 2011 | Jun 30, 2011 | — | $-0.54 | — | — |
Q4 2010 | Dec 31, 2010 | — | $-1.13 | — | — |
Q2 2010 | Jun 30, 2010 | — | $-1.91 | — | — |
Q4 2009 | Dec 31, 2009 | — | $-4.89 | — | — |
Q2 2009 | Jun 30, 2009 | — | $-1.20 | — | — |
Latest News
Frequently Asked Questions about COX.PA
What is COX.PA's current stock price?
What is the analyst price target for COX.PA?
What sector is Nicox S.A. in?
What is COX.PA's market cap?
Does COX.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to COX.PA for comparison